INL-International Iberian Nanotechnology Laboratory, Portugal.
Clinical Neurosciences Research Laboratory, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain.
Nanomedicine. 2020 Nov;30:102287. doi: 10.1016/j.nano.2020.102287. Epub 2020 Aug 13.
The abundance of cellular fibronectin (c-Fn) for ischemic stroke patients and the narrow time-window (<4.5 h) for the decision to administer the thrombolytic treatment with recombinant tissue plasminogen activator (rtPA) are challenging for the development of a point-of-care (PoC) diagnostic platform. We report a case of stratification of ischemic stroke patients based on a magnetoresistive biosensor platform that quantifies the c-Fn levels in a small volume of serum, within the clinically relevant time-window. Our PoC platform uses different ratios of biofunctionalized magnetic nanoparticles (MNPs) as immunoassay labels to adjust the sensitivity within the clinically relevant ranges for c-Fn (1-4 μg/mL). After optimizing the detection range, resolution, and sensitivity, our device was able to stratify ischemic stroke patients who developed hemorrhagic transformation, the main side-effect of rtPA, from those (both non-treated and treated with rtPA) who did not.
细胞纤维连接蛋白 (c-Fn) 在缺血性脑卒中患者中的含量丰富，而决定是否使用重组组织型纤溶酶原激活剂 (rtPA) 进行溶栓治疗的时间窗口很窄（<4.5 小时），这给即时检测（PoC）诊断平台的开发带来了挑战。我们报告了一个病例，该病例基于磁阻生物传感器平台对缺血性脑卒中患者进行分层，该平台可在小体积血清中定量检测 c-Fn 水平，时间窗口在临床相关范围内。我们的 PoC 平台使用不同比例的生物功能化磁性纳米颗粒 (MNP) 作为免疫分析标签，以在 c-Fn 的临床相关范围内（1-4μg/mL）调整灵敏度。在优化检测范围、分辨率和灵敏度后，我们的设备能够对发生出血性转化（rtPA 的主要副作用）的缺血性脑卒中患者进行分层，出血性转化是指未接受治疗和接受 rtPA 治疗的患者。
